Andrew Allen, Gritstone Oncology CEO
July 14, 2020 07:05 AM EDT
Bioregnum
Opinion

A neoanti­gen pi­o­neer says its tech is work­ing great. So what wrecked the share price?

Grit­stone On­col­o­gy was one of the orig­i­nal neoanti­gen up­starts, rais­ing cash and plan­ning to dis­rupt the im­muno-on­col­o­gy field with a bold new ap­proach …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

In­sil­i­co nabs $110M Se­ries E for AI drug dis­cov­ery af­ter stalling Hong Kong IPO plans

Ono li­cens­es rare blood dis­ease drug from Io­n­is for $280M up­front

Leg­end to dou­ble Carvyk­ti pro­duc­tion as it tar­gets block­buster sta­tus 

As­cle­tis’ not-so-great weight loss da­ta; Vi­vace’s $35M Se­ries D

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times